Loading organizations...
§ Private Profile · Shanghai, Shanghai, China
Biotech company developing molecular glue degraders to target undruggable proteins in oncology, inflammation, and rare diseases.
Degron Therapeutics is a Shanghai, China-based biotechnology company that develops small-molecule drugs called molecular glue degraders to target previously undruggable proteins. The enterprise utilizes its proprietary GlueXplorer platform, which integrates artificial intelligence with phenotypic and proteomic screening, to build a therapeutic pipeline focused on oncology, neuroscience, inflammation, and rare diseases. Operating with approximately 35 employees across its global footprint, the firm has generated a library of over 6,000 compounds and 60 novel diverse cores. Degron has raised $34.5 million in total funding, including a $22 million Series A round led by Med-Fine Capital, and secured a strategic partnership with Takeda Pharmaceuticals that includes an equity investment and up to $1.2 billion in potential milestone payments. The company was founded in 2021 by Lily Zou and Yong Cang, building upon scientific research originating from ShanghaiTech University.
Degron Therapeutics has raised $22.3M across 2 funding rounds.
Degron Therapeutics has raised $22.3M in total across 2 funding rounds.
Degron Therapeutics has raised $22.3M across 2 funding rounds. Most recently, it raised $290K Series A in December 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 27, 2023 | $290K Series A | Sujuan BA | — | Announced |
| Jun 10, 2022 | $22M Series A | Jing YU | Baidu Ventures, Co WIN Ventures, Dyee Capital, Neux Capital | Announced |
Degron Therapeutics has raised $22.3M in total across 2 funding rounds.
Degron Therapeutics's investors include Sujuan Ba, jing yu, Baidu Ventures, Co-win Ventures, Dyee Capital, NeuX Capital.